Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company, today announced that it will host Key Opinion Leader (KOL) meetings focused on BNC210 and the treatment of post-traumatic stress disorder (PTSD), on Friday, April 13, 2018 in New York and on Tuesday, April 17, 2018 in London.

The meeting in New York will feature a keynote presentation from:

- **Murray B. Stein, MD, PhD**, Distinguished Professor of Psychiatry and Family Medicine & Public Health, and Vice Chair for Clinical Research in Psychiatry at the University of California, San Diego (UCSD)

The meeting in London will feature keynote presentations from:

- **Mario F. Juruena, MD, MPhil, Dip CBT, MSc, PhD**, Clinical Senior Lecturer in Translational Psychiatry, Centre for Affective Disorders, Institute of Psychiatry, Psychology and Neuroscience, King’s College London
- **Edgar Jones, PhD**, Professor of the History of Medicine and Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King’s College London

Additionally, Bionomics management will provide an overview of the Company’s recent pipeline progress, including its ongoing Phase 2 study of BNC210 in PTSD.

A live audio webcast of the New York event can be accessed on the Bionomics website, [www.bionomics.com.au](http://www.bionomics.com.au). An archived replay will be available for 30 days after the live event concludes.

**FOR FURTHER INFORMATION PLEASE CONTACT:**

**Australia**

Monsoon Communications

Rudi Michelson

+613 9620 3333

[rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

**US**

Stern Investor Relations

Beth DelGiacco

+1 212 362 1200

[beth@sternir.com](mailto:beth@sternir.com)

**About Bionomics Limited**

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics’ lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine
Factors Affecting Future Performance
This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210, BNC101 and BNC105), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.